Core Insights - CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing a bladder-sparing therapeutic for bladder cancer patients [1][3] - Arthur Kuan, the Chairman & CEO, will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025 [1] - The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies [3] Company Information - CG Oncology is dedicated to commercializing a potential backbone therapeutic specifically for bladder cancer [1][3] - The company envisions a future where patients can live with dignity and improved quality of life due to its therapies [3] Event Details - The live audio webcast of the conference presentation will be accessible from the Investor Relations section of the company's website [2] - A replay of the webcast will be available for approximately 90 days after the live presentation [2]
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference